Illumina Inc (NASDAQ:ILMN)

CAPS Rating: 4 out of 5

The Company is a developer, manufacturer and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function.

Results 1 - 20 of 128 : 1 2 3 4 5 6 7 Next »

Recs

0
Member Avatar calanalysis (< 20) Submitted: 12/15/2015 12:22:44 PM : Underperform Start Price: $183.14 ILMN Score: +14.10

expensive machinery- much cheaper and more efficient products out there that still produces high % of DNA letters

Recs

0
Member Avatar anindakumars (< 20) Submitted: 11/17/2015 3:59:29 PM : Outperform Start Price: $173.48 ILMN Score: -9.90

pioneer in this field really

Recs

0
Member Avatar mtw4316 (37.69) Submitted: 11/14/2015 12:34:34 PM : Outperform Start Price: $159.17 ILMN Score: -10.13

Product
Optionality
Expensive

Recs

0
Member Avatar Dasinn (< 20) Submitted: 10/23/2015 9:45:04 AM : Outperform Start Price: $146.74 ILMN Score: +5.35

The supposed leader in DNA sequencing doing it at the cheapest cost. Personalized medicine will be huge in the future

Recs

0
Member Avatar CMFMikenpdx (26.10) Submitted: 10/6/2015 12:26:35 PM : Outperform Start Price: $193.24 ILMN Score: -23.28

just adding a note...
not that timing is important or that I am necessarily trying to time anything because well you can't do it reliably...
but the timing on this pick was pretty horrible. was near an all time high july 20 @ $240, was @ $210 as recently as Sep 18, and now...in 2 weeks -- down some 35%.

if I had to blame it on something, it's overall weakness in the biotech sector (naz bio index down 6-7% today as I type and off 26-27% from highs earlier this year. Then of course there was the Hillary tweet on drug pricing, which doesn't directly affect Illumina, but seemed to throw fuel on the fire and have a negative affect on the whole sector. Pacific BioSciences (PACB) announced the early launch of a competing sequencer and then Illumina pre-announced Q3 earnings that fell short of estimates and the market is selling off the company's stock to the tune of 15%. Down to $137 at one point today.

Recs

0
Member Avatar TMFBoiseKen (93.04) Submitted: 10/1/2015 4:35:21 PM : Outperform Start Price: $154.99 ILMN Score: -7.83

I can't believe I've never marked this company in CAPs. I've happily owned it for years. Coming in here after the great biotech rotation of 2015 to mark a green thumb is a wonderful chance to mark this moment in time.

Recs

0
Member Avatar mnunez721 (< 20) Submitted: 9/30/2015 12:58:35 PM : Outperform Start Price: $173.00 ILMN Score: -16.96

Illumina’s market power lies in revolutionizing the way pharmaceutical companies operate. The $300B industry of pharmaceuticals is a competitive industry with companies steering toward personalized (requiring genetic information) medicine. Illumina develops the equipment used by the pharmaceutical industry to carry out their genome sequencing. Not only is it an outstanding tech company, but it’s technology forms the backbone for the direction in which the pharmaceutical industry is trending.

Recs

0
Member Avatar justinr (64.78) Submitted: 9/5/2015 5:00:10 AM : Outperform Start Price: $195.76 ILMN Score: -23.21

DNA sequencing

Recs

0
Member Avatar optioncoach (84.72) Submitted: 8/23/2015 8:23:34 PM : Outperform Start Price: $184.29 ILMN Score: -23.06

Buying my favorites no matter what. These companies are not going anywhere and some I feel are just plain and simple too cheap. I will continue to sell volatility and buy quality until we cover the shorts and get that snap back rally. I don't see a bear market coming. This is the shake out.

Recs

0
Member Avatar JimmyLocos (31.49) Submitted: 8/21/2015 2:52:57 PM : Outperform Start Price: $200.43 ILMN Score: -23.30

DNA sequencing will continue to grow.

Recs

0
Member Avatar Lightmatter9 (< 20) Submitted: 7/17/2015 6:25:45 PM : Outperform Start Price: $240.84 ILMN Score: -28.95

Excellent management combined with a field of unlimited potential.

Recs

0
Member Avatar BentMike (52.35) Submitted: 7/17/2015 2:29:42 PM : Outperform Start Price: $239.21 ILMN Score: -28.76

Used extensively in academia and professional science on non-human subjects. Good stuff. great future.

Recs

0
Member Avatar dstwhit (24.22) Submitted: 6/24/2015 11:47:10 AM : Outperform Start Price: $222.97 ILMN Score: -24.86

strong leadership (glassdoor); rb; leader in genome sequencing in biotech industry; high rev/earnings growth and repeat product; innovative culture
but: p/e=77; biotech industry may have a correction coming

Recs

0
Member Avatar Justify (< 20) Submitted: 6/10/2015 1:53:03 PM : Outperform Start Price: $216.02 ILMN Score: -23.08

It's lead in gene sequencing backed by a surge in gene research for curing diseases bodes well.

Recs

0
Member Avatar jdbow (44.73) Submitted: 6/8/2015 10:44:08 AM : Outperform Start Price: $206.88 ILMN Score: -21.02

been thinking about this one for a while & the price took a nice drop today

Recs

0
Member Avatar DLester78 (53.33) Submitted: 6/2/2015 10:56:58 AM : Outperform Start Price: $203.96 ILMN Score: -19.28

Medicine squared

Recs

0
Member Avatar dscrugham (< 20) Submitted: 5/25/2015 7:09:06 PM : Outperform Start Price: $204.36 ILMN Score: -18.93

Great Rule Breaker and growing!!!

Recs

0
Member Avatar aminded45 (< 20) Submitted: 5/11/2015 10:13:00 PM : Outperform Start Price: $195.72 ILMN Score: -17.12

A great product at the right time. With a little regulatory help this stock could be a sure winner.

Recs

0
Member Avatar NickInvestments (< 20) Submitted: 1/30/2015 6:41:41 PM : Outperform Start Price: $195.37 ILMN Score: -21.16

Genetic reading and writing are massive future markets.

Featured Broker Partners